Gynecologic Department, Naestved Hospital, University of Copenhagen, Naestved, Denmark.
Ultrasound Obstet Gynecol. 2012 Oct;40(4):445-51. doi: 10.1002/uog.11118.
To evaluate the feasibility of ultrasound-guided radiofrequency ablation (USgRFA) for the treatment of women with symptomatic uterine fibroids in relation to volume of fibroid.
Forty-three women with symptomatic fibroids underwent USgRFA for treatment of uterine fibroids. Improvements in fibroid symptoms and quality of life were measured by the Uterine Fibroid Symptom and Quality of Life questionnaire scores at baseline and 3, 6 and 9 months after the intervention, and analyzed in relation to baseline fibroid volume. Volume reduction of fibroids was measured and the frequency of adverse events and re-interventions was recorded.
Following USgRFA, mean Symptom Severity Scores (SSS) decreased from 60.7 ± 17.8 to 31.2 ± 19.5, corresponding to an improvement of 48.6%. The total Health-Related Quality of Life (HRQOL) score improved by 46.4% from 55.6 ± 20.9 to 81.4 ± 16.6. There was no correlation between fibroid volume at baseline and improvement in SSS and HRQOL scores. Fibroid volume was reduced in all patients, by a mean of 69.7 ± 19.4%. Two (4.7%) patients underwent hysterectomy. No adverse events occurred.
USgRFA reduces fibroid symptom and size even in patients with larger fibroids. USgRFA is a promising new treatment for fibroids in gynecological settings and should be further investigated.
评估超声引导下射频消融（USgRFA）治疗有症状子宫肌瘤与肌瘤体积的关系。
43 名有症状的子宫肌瘤患者接受 USgRFA 治疗子宫肌瘤。通过子宫肌瘤症状和生活质量问卷评分在基线和干预后 3、6 和 9 个月评估子宫肌瘤症状和生活质量的改善情况，并与基线肌瘤体积进行分析。测量肌瘤体积减少情况，并记录不良事件和再次干预的频率。
USgRFA 后，平均症状严重程度评分（SSS）从 60.7±17.8 降至 31.2±19.5，对应改善 48.6%。健康相关生活质量（HRQOL）总评分从 55.6±20.9 提高至 81.4±16.6，提高了 46.4%。基线肌瘤体积与 SSS 和 HRQOL 评分的改善无相关性。所有患者的肌瘤体积平均减少了 69.7±19.4%。2 名（4.7%）患者行子宫切除术。无不良事件发生。
USgRFA 可减轻有症状的大肌瘤患者的肌瘤症状和大小。USgRFA 是妇科治疗子宫肌瘤的一种很有前途的新方法，应进一步研究。
